July 2026 FDA Recall Amlodipine And Olmesartan Medoxomil by Ascend Laboratories, Llc
D-0712-2026 - Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications

This Class II drug recall was voluntarily initiated by Ascend Laboratories, Llc on July 8, 2026 for the product Amlodipine And Olmesartan Medoxomil. The FDA reported the reason for recall as failed dissolution specifications; olmesartan medoxomil content below specifications. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0712-2026

Reason for Recall
Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications
Initiated
07-08-2026
Reported
07-29-2026
Quantity
6,192 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Ascend Laboratories, LLC
Nationwide in the USA
Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mg, 30 Tablets per bottle, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA; Distributed by: Ascend Laboratories, LLC., Parsnippany, NJ 07054. NDC: 67877-500-30

Batch or Lot Expiration Information

Lot# Lot 25121311, expiry 3/31/2028